2023
Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Muvvala S, Gan G, Morford K, Dziura J, Esserman D, Porter E, Chan P, Cornman D, Reynolds J, Yager J, Fiellin D, Edelman E. Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial. Journal Of Addiction Medicine 2023, 17: e388-e391. PMID: 37934538, PMCID: PMC10726383, DOI: 10.1097/adm.0000000000001192.Peer-Reviewed Original ResearchConceptsOpioid use disorderAlcohol use disorderTobacco use disorderHIV clinicUse disordersAddiction treatmentSubstance use disorder treatmentUse disorder treatmentMaintenance phaseRandomized trialsStaff preferencesImproved outcomesMultisite Randomized TrialImplementation facilitationDisorder treatmentControl phaseClinicCliniciansTreatment modelTreatmentDisordersSignificant differencesInterventionHigher proportionAddiction treatment modelsEfficacy of alcohol reduction interventions among people with HIV as evaluated by self-report and a phosphatidylethanol (PEth) outcome: protocol for a systematic review and individual participant data meta-analysis
Kane J, Allen I, Fatch R, Scheffler A, Emenyonu N, Puryear S, Chirayil P, So-Armah K, Kahler C, Magidson J, Conroy A, Edelman E, Woolf-King S, Parry C, Kiene S, Chamie G, Adong J, Go V, Cook R, Muyindike W, Morojele N, Blokhina E, Krupitsky E, Fiellin D, Hahn J. Efficacy of alcohol reduction interventions among people with HIV as evaluated by self-report and a phosphatidylethanol (PEth) outcome: protocol for a systematic review and individual participant data meta-analysis. BMJ Open 2023, 13: e070713. PMID: 37280036, PMCID: PMC10254608, DOI: 10.1136/bmjopen-2022-070713.Peer-Reviewed Original ResearchConceptsAlcohol useUnhealthy alcohol useSelf-reported measurementsAlcohol reduction interventionsEfficacy of interventionsAlcohol outcomesIndividual participant dataIntervention studiesAlcohol interventionsInformation biasesAdditional ethical approvalParticipants 15 yearsEffective interventionsSystematic reviewTreatment effectsParticipant dataHIV viral suppressionPrimary outcome variableReduction interventionsPooled treatment effectOutcome variablesInterventionInternational scientific meetingsSecondary outcomesViral suppressionContingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Fucito L, Ferguson T, Bedimo R, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Contingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial. Contemporary Clinical Trials 2023, 131: 107242. PMID: 37230168, PMCID: PMC10460633, DOI: 10.1016/j.cct.2023.107242.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingCohort StudiesCOVID-19HIV InfectionsHumansPandemicsRandomized Controlled Trials as TopicConceptsUnhealthy alcohol useLong-term abstinenceAlcohol useContingency managementAlcohol consumptionFormal alcohol treatmentShort-term abstinenceMotivational enhancement therapyGOV IDENTIFIERSecondary outcomesWeek 24Primary outcomeWeek 12Preliminary efficacyTreatment trialsPhysician managementEfficacy trialsMedical conditionsAlcohol treatmentExploratory outcomesEnhancement therapyAbstinenceTrialsCareHealthy activitiesFactors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use
Bahji A, Gordon K, Crystal S, Satre D, Wiliams E, Edelman E, Justice A. Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use. AIDS And Behavior 2023, 27: 2455-2462. PMID: 36622487, PMCID: PMC10225332, DOI: 10.1007/s10461-022-03972-3.Peer-Reviewed Original Research
2022
Contingency management and pre-exposure prophylaxis adherence support services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs
Sung M, Viera A, Esserman D, Tong G, Davidson D, Aiudi S, Bailey G, Buchanan A, Buchelli M, Jenkins M, John B, Kolakowski J, Lame A, Murphy S, Porter E, Simone L, Paris M, Rash C, Edelman E. Contingency management and pre-exposure prophylaxis adherence support services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs. Contemporary Clinical Trials 2022, 125: 107037. PMID: 36460267, PMCID: PMC9918697, DOI: 10.1016/j.cct.2022.107037.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsDrug UsersHIV InfectionsHumansPre-Exposure ProphylaxisRisk Reduction BehaviorSubstance Abuse, IntravenousConceptsAdherence support servicesHIV risk reductionPrEP adherenceContingency managementHybrid type 1 effectiveness-implementation trialHIV pre-exposure prophylaxisEffectiveness-implementation studyPre-exposure prophylaxisEffectiveness-implementation trialOpioid use disorderStrengths-based case managementRisk reductionSupport servicesCommunity-based programsPrEP initiationPrimary outcomeWeek 12Clinical trialsHIV preventionUse disordersCM sessionsCase managementBlood spotsPWIDStudy design
2020
All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors
Gordon K, Manhapra A, Crystal S, Dziura J, Edelman E, Skanderson M, Kerns R, Justice A, Tate J, Becker W. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. Drug And Alcohol Dependence 2020, 216: 108291. PMID: 33011662, PMCID: PMC7644145, DOI: 10.1016/j.drugalcdep.2020.108291.Peer-Reviewed Original ResearchConceptsMorphine equivalent daily doseCause mortalityLong-term opioid therapyTime-updated Cox regressionStrong dose-response relationshipUnnatural deathsEquivalent daily doseDose-response relationshipOpioid doseOpioid therapyUninfected patientsOpioid useDaily doseCox regressionMortality outcomesTherapy doseHigh doseMale veteransOverdose fatalitiesOverdose mortalityPLWHMortalityHIVPatientsDose
2019
Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain.
Merlin JS, Long D, Becker WC, Cachay ER, Christopolous KA, Claborn KR, Crane HM, Edelman E, Lovejoy TI, Mathews WC, Morasco BJ, Napravnik S, OʼCleirigh C, Saag MS, Starrels JL, Gross R, Liebschutz JM. Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 81: 231-237. PMID: 30865181, PMCID: PMC6522289, DOI: 10.1097/qai.0000000000001998.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidChronic PainFemaleFollow-Up StudiesHIV InfectionsHumansLogistic ModelsMaleMarijuana SmokingMarijuana UseMedical MarijuanaMiddle AgedMultivariate AnalysisOpioid-Related DisordersPrescription DrugsProspective StudiesSelf ReportSurveys and QuestionnairesTreatment OutcomeUnited StatesConceptsChronic painPain severityIndex visitOpioid useMultivariable binary logistic regression modelMarijuana useDiscontinuation of opioidsImproved pain outcomesMedian pain severityAIDS Research NetworkPrescription opioid usePrescribed opioid useIntegrated Clinical SystemsLogistic regression modelsBinary logistic regression modelOpioid discontinuationOpioid initiationOpioid prescribingOpioid prescriptionsPain outcomesClinical systemsHigher oddsLower oddsPainPLWHIntegration of care for HIV and opioid use disorder
Oldfield B, Muñoz N, McGovern M, Funaro M, Villanueva M, Tetrault J, Edelman E. Integration of care for HIV and opioid use disorder. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30882491, PMCID: PMC6588508, DOI: 10.1097/qad.0000000000002125.Peer-Reviewed Original ResearchConceptsHIV care settingsCare settingsClinical benefitTreatment settingsSystematic reviewBuprenorphine/naloxoneOpioid use disorderProvision of medicationsIntegration of careAntiretroviral therapyOpioid useMedication adherencePROSPERO databaseOvid MEDLINETreatment strategiesObservational studyHIVUse disordersModerate riskBehavioral interventionsScreening strategyOUDRisk reductionTreatmentUnique studies
2018
“No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder
Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, Tetrault JM, Edelman E. “No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. Journal Of Substance Use And Addiction Treatment 2018, 97: 28-40. PMID: 30577897, DOI: 10.1016/j.jsat.2018.11.007.Peer-Reviewed Original ResearchConceptsOpioid use disorderIntegration of HIVUse disordersClinical staffCare of HIVCommunity-based participatory research principlesBehavioral health integrationImproved patient outcomesEvidence-based treatmentsDiverse care settingsParticipatory research principlesPrimary carePatient outcomesPatient-centered policiesCare settingsHealth integrationHIVQualitative studyStages of changeClinic leadershipCare instrumentIntegrated carePatientsBehavioral healthMeasures of quality
2016
Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs
Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, Phillips K, Tetrault JM, Shah M, Fiellin DA, Blackstock O. Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs. AIDS And Behavior 2016, 21: 1025-1033. PMID: 27896552, PMCID: PMC5344709, DOI: 10.1007/s10461-016-1612-6.Peer-Reviewed Original ResearchConceptsPrimary care physiciansPre-exposure prophylaxisCare physiciansHIV pre-exposure prophylaxisHIV risk groupMore HIVClinic patientsRisk groupsGeneral internistsPWIDAcademic general internistsPractice characteristicsDisease preventionHIVPrEPProphylaxisPatientsPhysiciansCareDrugsOnline surveyInternistsHigher willingnessLower willingnessCentral roleA Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians
Blackstock OJ, Moore BA, Berkenblit GV, Calabrese SK, Cunningham CO, Fiellin DA, Patel VV, Phillips KA, Tetrault JM, Shah M, Edelman EJ. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. Journal Of General Internal Medicine 2016, 32: 62-70. PMID: 27778215, PMCID: PMC5215171, DOI: 10.1007/s11606-016-3903-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCross-Sectional StudiesFemaleHealth Knowledge, Attitudes, PracticeHealth PersonnelHealth Risk BehaviorsHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisOdds RatioPractice Patterns, Physicians'Pre-Exposure ProphylaxisPrimary Health CareSurveys and QuestionnairesConceptsPrimary care physiciansHIV care experienceCare physiciansPrEP adoptionPrEP awarenessPractice characteristicsHIV pre-exposure prophylaxisCare experiencesAcademic primary care physiciansHIV-positive patientsPre-exposure prophylaxisHealth care providersResultsThe survey response rateSectional Online SurveyPCP adoptionHIV careKey ResultsThe survey response ratePercent of respondentsRisk compensationSurvey response ratePrEP knowledgePrEP useSelf-rated knowledgeMultivariable analysisClinical championsThe impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy
Edelman E, Gordon K, Tate J, Becker W, Bryant K, Crothers K, Gaither, Gibert C, Gordon A, Marshall B, Rodriguez‐Barradas M, Samet J, Skanderson M, Justice A, Fiellin D. The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy. HIV Medicine 2016, 17: 728-739. PMID: 27186715, PMCID: PMC5053822, DOI: 10.1111/hiv.12377.Peer-Reviewed Original ResearchConceptsCD4 cell countBaseline CD4 cell countCell countPrescribed opioidsImmunosuppressive propertiesVeterans Aging Cohort Study (VACS) dataCD4 cell count recoveryAntiretroviral therapy responseCell count recoveryShort-term opioidsViral load suppressionCohort study dataOverall disease severityYear of initiationPrimary independent variableOpioid durationAntiretroviral therapyCount recoveryComorbid conditionsPharmacy dataOpioid propertiesTherapy responseOpioidsPatientsHIVHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection
2014
Substance use in older HIV-infected patients
Edelman EJ, Tetrault JM, Fiellin DA. Substance use in older HIV-infected patients. Current Opinion In HIV And AIDS 2014, 9: 317-324. PMID: 24824888, PMCID: PMC4175926, DOI: 10.1097/coh.0000000000000069.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersSubstance useTreatment optionsHealth consequencesPotential treatment optionStimulant use disorderRelated health consequencesOlder HIVAntiretroviral therapyHIVPatientsBrief counselingHealth outcomesEffective interventionsComplex needsMedicationsDisordersCounseling strategiesInterventionOutcomesTobaccoLife courseOptionsTherapy
2012
Combining Rapid HIV Testing and a Brief Alcohol Intervention in Young Unhealthy Drinkers in the Emergency Department: A Pilot Study
Edelman EJ, Dinh A, Radulescu R, Lurie B, D'Onofrio G, Tetrault JM, Fiellin DA, Fiellin LE. Combining Rapid HIV Testing and a Brief Alcohol Intervention in Young Unhealthy Drinkers in the Emergency Department: A Pilot Study. The American Journal Of Drug And Alcohol Abuse 2012, 38: 539-543. PMID: 22794939, PMCID: PMC3522092, DOI: 10.3109/00952990.2012.701359.Peer-Reviewed Original ResearchConceptsSexual risk reduction counselingSexual risk behaviorsRisk reduction counselingRapid HIV testingEmergency departmentRisk behaviorsReduction counselingHIV testingAlcohol useUnhealthy drinkersAlcohol consumptionMean age 26 yearsAverage weekly drinksImportant preventive servicesAlcohol Use Disorders Identification Test (AUDIT) scoresUnknown HIV statusRapid HIV testsUnhealthy alcohol useAge 26 yearsBrief alcohol interventionHIV testHIV statusRegular doctorPreventive servicesRisk populations